Catalyst Pharmaceuticals, Inc. provided revenue guidance for full year 2022. The Company forecasts 2022 full year total revenues to be in the range of between $195 million and $205 million, representing a 38%-45% increase in total revenues as compared to 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.76 USD | -3.37% | -2.17% | -6.25% |
Jun. 05 | Catalyst Pharmaceuticals Insider Sold Shares Worth $276,735, According to a Recent SEC Filing | MT |
May. 30 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.25% | 1.93B | |
+0.99% | 91.72B | |
0.00% | 39.44B | |
-10.35% | 34.47B | |
+64.64% | 26.7B | |
-16.15% | 15.13B | |
-6.98% | 13.27B | |
-11.77% | 11.74B | |
-49.19% | 10.54B | |
+8.09% | 9.41B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2022